MedinCell® is a pharmaceutical company at premarketing stage that develops innovative long-acting injectable medicines in many therapeutic areas. Products of our portfolio are based on our BEPO® technology and aim to ensure patient compliance, improve the effectiveness and accessibility of treatments, and reduce their environmental footprint. We collaborate with tier one pharmaceuticals companies and foundations to improve Global Health through new therapeutic options.
Year founded2003
Served areaWorldwide
Headcount147
Headquarters3 Rue des Frères Lumière, 34380 Jacou – France
25,143,553
IPOOct. 8, 2018
Stock exchange(s)Euronext Paris